Eva Vilarrasa

1.7k total citations
50 papers, 967 citations indexed

About

Eva Vilarrasa is a scholar working on Dermatology, Immunology and Surgery. According to data from OpenAlex, Eva Vilarrasa has authored 50 papers receiving a total of 967 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Dermatology, 25 papers in Immunology and 15 papers in Surgery. Recurrent topics in Eva Vilarrasa's work include Psoriasis: Treatment and Pathogenesis (25 papers), Hidradenitis Suppurativa and Treatments (21 papers) and Colorectal and Anal Carcinomas (15 papers). Eva Vilarrasa is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (25 papers), Hidradenitis Suppurativa and Treatments (21 papers) and Colorectal and Anal Carcinomas (15 papers). Eva Vilarrasa collaborates with scholars based in Spain, Switzerland and United Kingdom. Eva Vilarrasa's co-authors include L. Puig, Anna López‐Ferrer, Antonio Martorell, J.C. Pascual, Ignasi Gich, Marta Ferrán, Iván García, X. Bordas, J Rodríguez and D. Jiménez‐Gallo and has published in prestigious journals such as SHILAP Revista de lepidopterología, International Journal of Molecular Sciences and Journal of the American Academy of Dermatology.

In The Last Decade

Eva Vilarrasa

45 papers receiving 952 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Vilarrasa Spain 20 610 545 254 219 121 50 967
David Williams United States 17 843 1.4× 849 1.6× 318 1.3× 219 1.0× 152 1.3× 23 1.3k
X. Bordas Spain 17 356 0.6× 594 1.1× 85 0.3× 183 0.8× 176 1.5× 33 934
R. You Switzerland 11 812 1.3× 1.2k 2.2× 75 0.3× 79 0.4× 235 1.9× 17 1.3k
R.J.B. Driessen Netherlands 21 522 0.9× 760 1.4× 35 0.1× 74 0.3× 186 1.5× 40 1.0k
Jeffrey Zweegers Netherlands 14 245 0.4× 455 0.8× 86 0.3× 25 0.1× 99 0.8× 19 610
Robert E. Kalb United States 10 337 0.6× 546 1.0× 28 0.1× 89 0.4× 115 1.0× 18 686
Michael Bukhalo United States 10 361 0.6× 518 1.0× 14 0.1× 90 0.4× 79 0.7× 18 668
J.M. Carrascosa Spain 15 201 0.3× 400 0.7× 13 0.1× 88 0.4× 121 1.0× 32 571
H Both Netherlands 6 198 0.3× 165 0.3× 171 0.7× 281 1.3× 31 0.3× 8 671
Michael Klaber United Kingdom 14 336 0.6× 373 0.7× 20 0.1× 161 0.7× 67 0.6× 20 615

Countries citing papers authored by Eva Vilarrasa

Since Specialization
Citations

This map shows the geographic impact of Eva Vilarrasa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Vilarrasa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Vilarrasa more than expected).

Fields of papers citing papers by Eva Vilarrasa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Vilarrasa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Vilarrasa. The network helps show where Eva Vilarrasa may publish in the future.

Co-authorship network of co-authors of Eva Vilarrasa

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Vilarrasa. A scholar is included among the top collaborators of Eva Vilarrasa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Vilarrasa. Eva Vilarrasa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Grau‐Pérez, Mercè, Alejandro Molina‐Leyva, Antonio Martorell, et al.. (2025). ADOLESBIO-HS: A Real-World Multicenter Case Series on the Effectiveness and Safety of Adalimumab in Adolescents with Moderate-to-Severe Hidradenitis Suppurativa. Dermatology. 241(5-6). 1–7.
2.
Cantó, Elisabet, Marta Prado, Eva Vilarrasa, et al.. (2025). Transcriptomic Identification of Immune-Related Hubs as Candidate Predictor Biomarkers of Therapeutic Response in Psoriasis. International Journal of Molecular Sciences. 26(17). 8118–8118.
3.
Vilarrasa, Eva, Irene Fuertes, Gemma Martín‐Ezquerra, et al.. (2024). Real‐world adalimumab survival and discontinuation factors in hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology. 39(1). 221–229. 1 indexed citations
4.
Vilarrasa, Eva, et al.. (2023). Unmet clinical needs, burden of disease and treatment patterns in hidradenitis suppurativa: Real‐world experience from Spain. SHILAP Revista de lepidopterología. 3(1). 347–357. 1 indexed citations
5.
Rivera, R., Fernando Alfageme, Eva Vilarrasa, et al.. (2023). The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermo-Sifiliográficas. 114(9). 755–762. 3 indexed citations
6.
Romaní, Jorge, et al.. (2023). Management of hidradenitis suppurativa tunnels using drainage setons: A retrospective multicentric study. Journal of the American Academy of Dermatology. 90(4). 868–870. 2 indexed citations
7.
Vilarrasa, Eva, et al.. (2023). [Translated article] Glucagon-Like Peptide-1 Agonists for Treating Obesity in Patients With Immune-Mediated Skin Diseases. Actas Dermo-Sifiliográficas. 115(1). T56–T65. 1 indexed citations
8.
9.
Rivera, R., Fernando Alfageme, Eva Vilarrasa, et al.. (2023). [Artículo traducido] Efectividad de guselkumab en pacientes con hidradenitis supurativa en condiciones de práctica clínica: estudio retrospectivo y multicéntrico en España. Actas Dermo-Sifiliográficas. 114(9). T755–T762. 2 indexed citations
10.
Martí, Nuria, et al.. (2023). Gluteal Hidradenitis Suppurativa: Analysis of 83 Patients. Actas Dermo-Sifiliográficas. 115(2). 137–142. 1 indexed citations
11.
López‐Ferrer, Anna, et al.. (2022). A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. International Journal of Clinical Pharmacy. 44(3). 725–730. 8 indexed citations
12.
Iznardo, Helena, Eva Vilarrasa, Anna López‐Ferrer, & L. Puig. (2021). Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. British Journal of Dermatology. 185(3). 660–662. 17 indexed citations
13.
14.
Rivera, R., Eva Vilarrasa, M. Ribera, et al.. (2020). Unmet needs in patients with moderate-to-severe plaque psoriasis treated with methotrexate in real world practice: FirST study. Journal of Dermatological Treatment. 33(3). 1329–1338. 8 indexed citations
15.
Romaní, J., Eva Vilarrasa, Flávia Vasques Bittencourt, et al.. (2020). Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis. Dermatology. 237(3). 365–371. 26 indexed citations
16.
Zouboulis, Christos C., Hendrik H.G. Hansen, Raffaele Dante Caposiena, et al.. (2019). Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa. Dermatology. 236(1). 25–30. 51 indexed citations
17.
Vilarrasa, Eva, et al.. (2018). Serum Zinc Levels in Hidradenitis Suppurativa: A Case–Control Study. American Journal of Clinical Dermatology. 19(5). 771–777. 22 indexed citations
18.
Vilarrasa, Eva, et al.. (2016). ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice. Journal of the American Academy of Dermatology. 74(6). 1066–1072. 53 indexed citations
19.
20.
Yélamos, Oriol, et al.. (2014). Acute Severe Methotrexate Toxicity in Patients with Psoriasis: A Case Series and Discussion. Dermatology. 229(4). 306–309. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Williams Breakdown of academic impact, for papers by X. Bordas Breakdown of academic impact, for papers by R. You Breakdown of academic impact, for papers by R.J.B. Driessen Breakdown of academic impact, for papers by Jeffrey Zweegers Breakdown of academic impact, for papers by Robert E. Kalb Breakdown of academic impact, for papers by Michael Bukhalo Breakdown of academic impact, for papers by J.M. Carrascosa Breakdown of academic impact, for papers by H Both Breakdown of academic impact, for papers by Michael Klaber
Rankless by CCL
2026